Quickstart Highlights Tirzepatide is a dual GLP-1/GIP receptor agonist it engages two incretin pathways to curb appetite and improve glycemic control [1] and has been studied for substantial weight loss and broad metabolic improvement in obesity and type 2 diabetes [2] [3]
Trulicity (generic name: dulaglutide) is a single-action medication that mimics the hormone GLP-1, while Mounjaro is a dual-action medication and mimics the hormones GLP-1 and GIP
It reports published research it doesnt recommend that you use, obtain, or supply anything
A legitimate business can still have poor operational practices
Additional serious warnings from FDA prescribing information: severe gastrointestinal adverse reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, hypoglycemia risk with insulin or insulin secretagogues, diabetic retinopathy and vision changes in patients with type 2 diabetes, depression or mood changes requiring clinical monitoring, and pulmonary aspiration risk during general anesthesia or deep sedation
:max_bytes(150000):strip_icc()/VWH-GettyImages-2275860768-a6f6e63304e048d0a829844c1dacbd8d.jpg)
